DOCSLIB.ORG

Products for Human Pluripotent Stem Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Products for Human Pluripotent Stem Cells HUMAN PLURIPOTENT STEM CELLS Products for Your Research Scientists Helping Scientists™ | WWW.STEMCELL.COM HUMAN PLURIPOTENT STEM CELLS 2 STEMCELL Technologies Inc. TABLE OF CONTENTS Reprogram Differentiate 4 Reprogramming 24 Differentiation 4 ReproRNA™-OKSGM 24 STEMdiff™ Overview 5 ReproTeSR™ 5 Erythroid Progenitor Reprogramming Kit 25 Mesoderm Differentiation + 5 CD34 Progenitor Reprogramming Kit 25 Mesoderm Differentiation Pathways 6 TeSR™-E7™ 26 STEMdiff™ Mesoderm Induction Medium 26 STEMdiff™ Mesenchymal Progenitor Kit Maintain 27 STEMdiff™ Endothelial Differentiation Kit 28 STEMdiff™ Hematopoietic System 7 Maintenance 31 STEMdiff™ Cardiomyocyte System 7 TeSR™ Overview 32 STEMdiff™ Myogenic System 8 mTeSR™ Plus 33 STEMdiff™ Kidney Organoid Kit 10 TeSR™-AOF 12 mTeSR™1 34 Ectoderm Differentiation 12 TeSR™-E8™ 34 Ectoderm Differentiation Pathways 35 STEMdiff™ Neural System 13 Scale-Up 37 STEMdiff™ Cerebral Organoid Kit 13 mTeSR™3D 38 STEMdiff™ Dorsal and Ventral Forebrain Organoid Kits 13 TeSR™-E8™3D 39 BrainPhys™ Neuronal Medium 39 NeuroFluor™ NeuO 14 Naïve Induction and Maintenance 40 STEMdiff™ Neural Crest Differentiation Kit 14 RSeT™ Feeder-Free 41 STEMdiff™ Microglia Culture System 15 NaïveCult™ 15 hPSC Naïve State qPCR Array 42 Endoderm Differentiation 42 Endoderm Differentiation Pathways 16 Matrices 43 STEMdiff™ Definitive Endoderm Kit 16 Vitronectin XF™ & CellAdhere™ Laminin-521 43 hPSC-Derived Endoderm qPCR Array 44 STEMdiff™ Intestinal Organoid Kit 17 Dissociation Reagents 45 STEMdiff™ Pancreatic Progenitor Kit 17 ReLeSR™ 46 STEMdiff™ Lung Progenitor Kit 17 Gentle Cell Dissociation Reagent 47 STEMdiff™ Branching Lung Organoid Kit 17 ACCUTASE™ & Dispase 48 Flexible User-Directed Differentiation Genome Edit 48 STEMdiff™ APEL™2 & APEL™2-LI 18 Genome Editing 48 TeSR™-E5 & TeSR™-E6 18 CloneR™ 19 ArciTect™ Accessory Products Characterize 49 Small Molecules & Cytokines 50 AggreWell™ Plates 20 Cell Quality Characterization 51 Antibodies 20 hPSC Genetic Analysis Kit 51 GloCell™ Fixable Viability Dyes 21 STEMdiff™ Trilineage Differentiation Kit 52 Annexin V Dyes 21 hPSC Trilineage Differentiation qPCR Array 53 Product Listing Cryopreserve 22 Cryopreservation 58 References 22 mFreSR™ & FreSR™-S 22 CryoStor® CS10 23 ThawSTAR® CFT2 WWW.STEMCELL.COM 3 HUMAN PLURIPOTENT STEM CELLS Reprogramming ReproRNA™-OKSGM Generate iPS Cells Using a Non-Integrating Reprogramming Vector ReproRNA™-OKSGM is a single-stranded RNA replicon vector that contains five reprogramming factors: OCT4, KLF4, SOX2, GLIS1, and c-MYC, as well as a puromycin-resistance gene. This RNA vector reprograms human somatic cells, such as fibroblasts, into induced pluripotent stem (iPS) cells with high efficiency and only requires a single transfection. As shown in Figure 1, using ReproRNA™-OKSGM with ReproTeSR™ reprogramming medium allows for iPS cell colony generation under feeder-free conditions with similar reprogramming efficiency to feeder- based systems. ReproRNA™-derived human iPS cell colonies also express markers of undifferentiated cells and retain a normal karyotype. Subsequently, human iPS cells generated with ReproRNA™-OKSGM can be maintained in a TeSR™ maintenance medium and further differentiated into cells of all three germ layers. Adult Human Dermal Fibroblasts (%) Why Use ReproRNA™-OKSGM? NON-VIRAL. Non-integrating vector system. SELF-REPLICATING VECTOR. Only a single transfection is required. TM ALL-IN-ONE. Vector contains all reprogramming factors. HIGHLY EFFICIENT. Comparable fibroblast 1 Figure 1. ReproRNA™-OKSGM Vector Efficiently Reprograms reprogramming efficiency to Sendai virus. Fibroblasts Human dermal fibroblasts were transfected with the ReproRNA™-OKSGM vector and reprogrammed under feeder-dependent (standard KOSR-containing human embryonic stem (ES) cell medium on inactivated mouse embryonic fibroblasts Learn more at (iMEFs)) or feeder-free conditions (ReproTeSR™ on Corning®Matrigel®). www.stemcell.com/ReproRNA-OKSGM The efficiency of reprogramming fibroblasts with ReproRNA™-OKSGM and ReproTeSR™ is comparable to that reported with Sendai virus.1 (n ≥ 6; data shown are mean ± SD) Somatic Cells Mesenchymal – Epithelial iPS Cell Colony (e.g. Fibroblasts) Transition Reprogramming with ReproRNA™-OKSGM Plate Transfect somatic cells Pick cells with ReproRNA™ colonies Day 0 1 6 8 15 20 - 28 + Puromycin + Puromycin + B18R + B18R Culture Somatic Cell TeSR™ Growth Medium ReproTeSR™ ReproTeSR™ Medium Medium Medium* *mTeSR™1, mTeSR™ Plus, TeSR™-E8™, or TeSR™-AOF Figure 2. Schematic for Reprogramming with ReproRNA™-OKSGM Somatic cells are transfected with ReproRNA™-OKSGM at day 0 and cultured in Growth Medium (containing puromycin). After 5 days of puromycin selection post-transfection, cells are cultured in ReproTeSR™ for the remainder of the reprogramming induction phase until iPS cell colonies emerge. Recombinant B18R Protein is also added during the first 2 weeks after transfection to inhibit the interferon response and increase cell viability. Typically, by day 20, iPS cell colonies are large enough to be isolated and propagated in a TeSR™ maintenance medium. 1 4 STEMCELL Technologies Inc. ReproTeSR™ Reproducibly Generate High Numbers of Integrated Sets of Tools for Human iPS Cell Colonies Reprogramming Human Blood Cells Erythroid Progenitor CD34+ Progenitor ReproTeSR™ is a complete, defined, xeno-free, and feeder-free Reprogramming Kit Reprogramming Kit reprogramming medium optimized for the generation of human iPS cells. Use ReproTeSR™ during the induction phase of reprogramming to produce more iPS cell colonies than with traditional KOSR-containing human ES cell media. Human iPS cell colonies generated with ReproTeSR™ express undifferentiated • Enrich cells with • Enrich cells with RosetteSep™ cell markers and exhibit more defined borders, compact RosetteSep™ and and SepMate™ morphology, and reduced differentiation. SepMate™ • Isolate CD34+ cells ReproTeSR™ was optimized for reprogramming blood cells • No isolation step required with EasySep™* and seamlessly integrates with RosetteSep™, SepMate™, • Expand erythroid cells with • Expand CD34+ cells with EasySep™, and StemSpan™ products for isolating and StemSpan™ SFEM II + Erythroid StemSpan™ SFEM II + CD34+ expanding hematopoietic cells. It can also be used to reprogram Expansion Supplement Expansion Supplement other somatic cell types and can be paired with ReproRNA™- • Reprogram cells with • Reprogram cells with OKSGM for reprogramming fibroblasts. iPS cells generated ReproTeSR™ ReproTeSR™ with ReproTeSR™ can be subsequently cultured in a TeSR™ maintenance medium and differentiated with the STEMdiff™ *EasySep™ magnet is not included with the CD34+ Progenitor Reprogramming Kit and must suite of products to cells of all three lineages. Purchase be purchased separately. ReproTeSR™ individually or as part of the Erythroid or CD34+ Progenitor Reprogramming Kits. Blood Cells Attached Blood Cells Pre-iPS Cell Colony iPS Cell Colony (e.g. CD34+ Cells) ReproTeSR™ Blood Reprogramming Timeline Transfect or transduce blood cells Add Pick iPS cell colonies and with reprogramming factors ReproTeSR™ maintain in TeSR™ medium Day 0 3 5 7 21 - 28 Full-medium change daily Culture ReproTeSR™ Medium StemSpan™ + Supplement ReproTeSR™ TeSR™ Medium* StemSpan™ + Supplement *mTeSR™1, mTeSR™ Plus, TeSR™-E8™, or TeSR™-AOF Figure 3. Schematic of ReproTeSR™ Blood Reprogramming Timeline ReproTeSR™ is used during the entire induction phase of reprogramming (days 3 to 21). On days 3 and 5, ReproTeSR™ is added to StemSpan™ growth medium (in a fed-batch manner) to facilitate attachment of transfected cells. Attached cells are further cultured in ReproTeSR™ with daily full media changes until putative iPS cell colonies emerge (days 21 to 28). iPS cell colonies can then be isolated and propagated in a TeSR™ maintenance medium. ReproTeSR™ StemSpan™ + Supplement Learn more at www.stemcell.com/ReproTeSR 3 WWW.STEMCELL.COM 5 HUMAN PLURIPOTENT STEM CELLS TeSR™-E7™ Generate iPS Cells from Fibroblasts Without Why Use TeSR™-E7™? Feeders or Animal Components IDENTIFY AND SELECT COLONIES EASILY. TeSR™-E7™ is a defined, animal component-free (ACF) Pre- screened components ensure high-quality colony reprogramming culture medium optimized for the generation of morphology for improved manual selection. human iPS cells without the use of feeders. It is based on the E7 RAPID SUBCLONING. Reduced differentiation and formulation published by the laboratory of Dr. James Thomson.2 fibroblast growth enables rapid establishment of TeSR™-E7™ is specifically formulated to limit fibroblast overgrowth, homogeneous human iPS cell cultures. resulting in colonies with easily recognizable ES cell-like morphology. REPRODUCIBLE EFFICIENCY. Feeder-free, defined formulation facilitates reproducibly efficient human iPS A B cell generation. Learn more at www.stemcell.com/TeSR-E7 Figure 4. Primary iPS Cell Colonies Derived in TeSR™-E7™ Have Defined Borders and Reduced Differentiation (A) TeSR™-E7™ yields easily recognizable iPS cell colonies with defined borders. (B) Unqualified components can result in colonies that have poorly defined edges and higher levels of differentiation. Representative colonies from adult human fibroblasts reprogrammed with episomal vectors containing OCT4, SOX2, KLF4, and c-MYC are shown. Somatic Cells Mesenchymal - Pre-iPS Cell iPS Cell Established iPS (e.g. Fibroblasts) Epithelial Transition Colony Colony Cell Line Reprogramming Timeline Transfect or transduce somatic cells Change medium Pick iPS cell colonies and with reprogramming
Load more

Recommended publications
  • Stem Cells Cloning Prons & Cons
    & Trans g ge in n n e s o l i s C Cloning and Transgenesis Kalodimou, Clon Transgen 2014, 3:3 ISSN: 2168-9849 DOI: 10.4172/2168-9849.1000127 Short Communication Open Access Stem Cells Cloning Prons & Cons Vasiliki E Kalodimou* Research and Regenerative Medicine Department, IASO Maternity Hospital, Athens, Greece *Corresponding author: Vasiliki E Kalodimou, Head of Flow Cytometry-Research and Regenerative Medicine Department, IASO Maternity Hospital, Athens, Greece, Tel: 0030-210-618-5; E-mail: [email protected] Rec date: May 16, 2014; Acc date: Jun 30, 2014; Pub date: July 2, 2014 Copyright: © 2014 Kalodimou VE. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Stem Cell Cloning the target cell. In principle, this may be dangerous, because the gene therapy vector can potentially modify the activity of neighboring genes Over the last several decades, the ideas of both stem cell research (positively or negatively) in close proximity to the insertion site or and cloning have received significantly more attention than ever even inactivate host genes by integrating into them [6]. These before; currently there are 23 open/completed clinical trials, together phenomena may contribute to the malignant transformation of the with a great deal of controversy. This new advances in medical targeted cells, ultimately resulting in cancer. Another major limitation technology had provide scientific with a new view of potential to help of using adult stem cells is that it is relatively difficult to maintain the people suffering from various diseases as well as to help them recover stem cell state during ex vivo manipulations.
    [Show full text]
  • Human Cloning: Must We Sacrifice Medical Research in the Name of a Total Ban?
    S. HRG. 107–812 HUMAN CLONING: MUST WE SACRIFICE MEDICAL RESEARCH IN THE NAME OF A TOTAL BAN? HEARING BEFORE THE COMMITTEE ON THE JUDICIARY UNITED STATES SENATE ONE HUNDRED SEVENTH CONGRESS SECOND SESSION FEBRUARY 5, 2002 Serial No. J–107–55 Printed for the use of the Committee on the Judiciary ( U.S. GOVERNMENT PRINTING OFFICE 83–684 PDF WASHINGTON : 2002 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2250 Mail: Stop SSOP, Washington, DC 20402–0001 VerDate Feb 1 2002 09:13 Jan 16, 2003 Jkt 083684 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 C:\HEARINGS\83684.TXT SJUD4 PsN: CMORC COMMITTEE ON THE JUDICIARY PATRICK J. LEAHY, Vermont, Chairman EDWARD M. KENNEDY, Massachusetts ORRIN G. HATCH, Utah JOSEPH R. BIDEN, JR., Delaware STROM THURMOND, South Carolina HERBERT KOHL, Wisconsin CHARLES E. GRASSLEY, Iowa DIANNE FEINSTEIN, California ARLEN SPECTER, Pennsylvania RUSSELL D. FEINGOLD, Wisconsin JON KYL, Arizona CHARLES E. SCHUMER, New York MIKE DEWINE, Ohio RICHARD J. DURBIN, Illinois JEFF SESSIONS, Alabama MARIA CANTWELL, Washington SAM BROWNBACK, Kansas JOHN EDWARDS, North Carolina MITCH MCCONNELL, Kentucky BRUCE A. COHEN, Majority Chief Counsel and Staff Director SHARON PROST, Minority Chief Counsel MAKAN DELRAHIM, Minority Staff Director (II) VerDate Feb 1 2002 09:13 Jan 16, 2003 Jkt 083684 PO 00000 Frm 00002 Fmt 5904 Sfmt 5904 C:\HEARINGS\83684.TXT SJUD4 PsN: CMORC C O N T E N T S STATEMENTS OF COMMITTEE MEMBERS Page Brownback, Hon.
    [Show full text]
  • Multipotent Cell Types in Primary Fibroblast Cell Lines Used to Clone Pigs Using Somatic Cell Nuclear Transfer Sharon J
    & Trans Harrison et al., Clon Transgen 2015, 4:2 g ge in n n e DOI: 10.4172/2168-9849.1000136 s o l i s C Cloning & Transgenesis ISSN: 2168-9849 Research Article Open Access Multipotent Cell Types in Primary Fibroblast Cell Lines Used to Clone Pigs using Somatic Cell Nuclear Transfer Sharon J. Harrison, Luke F.S. Beebe, Ivan Vassiliev, Stephen M. McIlfatrick and Mark B. Nottle* Reproductive Biotechnology Group, Centre for Stem Cell Research, Robinson Institute School of Paediatrics and Reproductive Health, University of Adelaide, Adelaide, South Australia, 5005, Australia Abstract We have previously demonstrated that the use of porcine mesenchymal stem cells (MSCs) isolated from the bone marrow can increase the proportion of somatic cell nuclear transfer (SCNT) embryos that develop to the blastocyst stage compared with adult fibroblasts obtained from the same animal. The aim of the present study was to determine if MSCs are also present in primary cultures of adult fibroblasts which are commonly used for cloning live animals. To do this we chose a primary culture of adult fibroblasts that we had previously used to clone pigs. Single cell clones were isolated using low-density plating. After seven days of culture 63% of colonies displayed typical fibroblast morphology, while the remainder appeared cobblestone-like in appearance. Two of the 57 clones that displayed fibroblast morphology differentiated into adipocytes but not chondrocytes or osteocytes (uni-potent clones). Three of the 33 cobblestone-like clones differentiated into chondrocytes only, while 3 differentiated into adipocytes and chondrocytes but not osteocytes (bi-potent clones). One of the bi-potent cobblestone-like clones was then used for SCNT and in vitro development compared with a fibroblast-like clone which did not differentiate.
    [Show full text]
  • A Simple Bioreactor-Based Method to Generate Kidney Organoids from Pluripotent Stem Cells
    bioRxiv preprint doi: https://doi.org/10.1101/237644; this version posted December 20, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. A simple bioreactor-based method to generate kidney organoids from pluripotent stem cells Aneta Przepiorskia†, Veronika Sandera†, Tracy Tranb, Jennifer A. Hollywooda, Brie Sorrensona, Jen-Hsing Shiha, Ernst J. Wolvetangc, Andrew P. McMahonb, Teresa M. Holm a, Alan J. Davidson a * a Department of Molecular Medicine & Pathology, University of Auckland, New Zealand. b Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, USA. c Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Australia. † These authors contributed equally * Corresponding author: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/237644; this version posted December 20, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Summary Kidney organoids generated from human pluripotent stem cells have the potential to revolutionize how kidney development and injury are studied. Current protocols are technically complex and suffer from poor reproducibility and high reagent costs restricting scalability. To overcome these issues, we have established a simple, inexpensive and robust method to grow kidney organoids in bulk from human induced pluripotent stem cells. Our organoids develop tubular structures by day (d) 8 and show optimal tissue morphology at d14. A comparison with fetal human kidney suggests that d14 organoid renal structures most closely resemble ‘capillary loop’ stage nephrons.
    [Show full text]
  • The WNT Target SP5 Negatively Regulates WNT Transcriptional Programs in Human Pluripotent Stem Cells
    ARTICLE DOI: 10.1038/s41467-017-01203-1 OPEN The WNT target SP5 negatively regulates WNT transcriptional programs in human pluripotent stem cells Ian J. Huggins1, Tomas Bos1, Olivia Gaylord1, Christina Jessen1, Brianna Lonquich1, Angeline Puranen1, Jenna Richter1, Charlotte Rossdam1, David Brafman2, Terry Gaasterland 3 & Karl Willert 1 The WNT/β-catenin signaling pathway is a prominent player in many developmental pro- cesses, including gastrulation, anterior–posterior axis specification, organ and tissue devel- opment, and homeostasis. Here, we use human pluripotent stem cells (hPSCs) to study the dynamics of the transcriptional response to exogenous activation of the WNT pathway. We describe a mechanism involving the WNT target gene SP5 that leads to termination of the transcriptional program initiated by WNT signaling. Integration of gene expression profiles of wild-type and SP5 mutant cells with genome-wide SP5 binding events reveals that SP5 acts to diminish expression of genes previously activated by the WNT pathway. Furthermore, we show that activation of SP5 by WNT signaling is most robust in cells with developmental potential, such as stem cells. These findings indicate a mechanism by which the develop- mental WNT signaling pathway reins in expression of transcriptional programs. 1 Department of Cellular & Molecular Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0695, USA. 2 School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ 85287, USA. 3 University of California San Diego and Scripps Institution of Oceanography, Scripps Genome Center, 9500 Gilman Drive, La Jolla, CA 92093-0202, USA. Correspondence and requests for materials should be addressed to T.G.
    [Show full text]
  • Replication Study: Wnt Activity Defines Colon Cancer Stem Cells and Is
    REPLICATION STUDY Replication Study: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment Anthony Essex1, Javier Pineda1, Grishma Acharya2, Hong Xin2, James Evans1, Reproducibility Project: Cancer Biology* 1PhenoVista Biosciences, San Diego, United States; 2Explora BioLabs Inc, San Diego, United States Abstract As part of the Reproducibility Project: Cancer Biology we published a Registered Report (Evans et al., 2015), that described how we intended to replicate selected experiments from the paper ‘Wnt activity defines colon cancer stem cells and is regulated by the microenvironment’ (Vermeulen et al., 2010). Here, we report the results. Using three independent primary spheroidal colon cancer cultures that expressed a Wnt reporter construct we observed high Wnt activity was associated with the cell surface markers CD133, CD166, and CD29, but not CD24 and CD44, while the original study found all five markers were correlated with high Wnt activity (Figure 2F; Vermeulen et al., 2010). Clonogenicity was highest in cells with high Wnt activity and clonogenic potential of cells with low Wnt activity were increased by myofibroblast-secreted factors, including HGF. While the effects were in the same direction as the original study (Figure 6D; Vermeulen et al., 2010) whether statistical significance was reached among the different conditions varied. When tested in vivo, we did not find a difference in tumorigenicity between high and low Wnt activity, while the original study found cells with high Wnt activity were more effective in inducing tumors (Figure 7E; Vermeulen et al., 2010). Tumorigenicity, however, was increased with *For correspondence: myofibroblast-secreted factors, which was in the same direction as the original study (Figure 7E; [email protected]; Vermeulen et al., 2010), but not statistically significant.
    [Show full text]
  • Targeting Chemoresistant Colorectal Cancer Via Systemic Administration of a BMP7 Variant
    Oncogene (2020) 39:987–1003 https://doi.org/10.1038/s41388-019-1047-4 ARTICLE Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant 1 1 1 1 1 Veronica Veschi ● Laura R. Mangiapane ● Annalisa Nicotra ● Simone Di Franco ● Emanuela Scavo ● 1 1 2 1 1 1 Tiziana Apuzzo ● Davide S. Sardina ● Micol Fiori ● Antonina Benfante ● Maria L. Colorito ● Gianfranco Cocorullo ● 3,4 1 5 5 6 Felice Giuliante ● Calogero Cipolla ● Giuseppe Pistone ● Maria Rita Bongiorno ● Aroldo Rizzo ● 7 7 7 7 5 3,4 Courtney M. Tate ● Xiaohua Wu ● Scott Rowlinson ● Louis F. Stancato ● Matilde Todaro ● Ruggero De Maria ● Giorgio Stassi1 Received: 10 April 2019 / Revised: 23 September 2019 / Accepted: 25 September 2019 / Published online: 7 October 2019 © The Author(s) 2019. This article is published with open access Abstract Despite intense research and clinical efforts, patients affected by advanced colorectal cancer (CRC) have still a poor prognosis. The discovery of colorectal (CR) cancer stem cell (CSC) as the cell compartment responsible for tumor initiation and propagation may provide new opportunities for the development of new therapeutic strategies. Given the reduced 1234567890();,: 1234567890();,: sensitivity of CR-CSCs to chemotherapy and the ability of bone morphogenetic proteins (BMP) to promote colonic stem cell differentiation, we aimed to investigate whether an enhanced variant of BMP7 (BMP7v) could sensitize to chemotherapy- resistant CRC cells and tumors. Thirty-five primary human cultures enriched in CR-CSCs, including four from chemoresistant metastatic lesions, were used for in vitro studies and to generate CR-CSC-based mouse avatars to evaluate tumor growth and progression upon treatment with BMP7v alone or in combination with standard therapy or PI3K inhibitors.
    [Show full text]
  • Telomere Shortening and Apoptosis in Telomerase-Inhibited Human Tumor Cells
    Downloaded from genesdev.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Telomere shortening and apoptosis in telomerase-inhibited human tumor cells Xiaoling Zhang,1 Vernon Mar,1 Wen Zhou,1 Lea Harrington,2 and Murray O. Robinson1,3 1Department of Cancer Biology, Amgen, Thousand Oaks, California 91320 USA; 2Amgen Institute/Ontario Cancer Institute, Toronto, Ontario M5G2C1 Canada Despite a strong correlation between telomerase activity and malignancy, the outcome of telomerase inhibition in human tumor cells has not been examined. Here, we have addressed the role of telomerase activity in the proliferation of human tumor and immortal cells by inhibiting TERT function. Inducible dominant-negative mutants of hTERT dramatically reduced the level of endogenous telomerase activity in tumor cell lines. Clones with short telomeres continued to divide, then exhibited an increase in abnormal mitoses followed by massive apoptosis leading to the loss of the entire population. This cell death was telomere-length dependent, as cells with long telomeres were viable but exhibited telomere shortening at a rate similar to that of mortal cells. It appears that telomerase inhibition in cells with short telomeres lead to chromosomal damage, which in turn trigger apoptotic cell death. These results provide the first direct evidence that telomerase is required for the maintenance of human tumor and immortal cell viability, and suggest that tumors with short telomeres may be effectively and rapidly killed following telomerase inhibition. [Key Words: TERT; telomere; dominant negative; proliferation; cancer] Received June 4, 1999; revised version accepted August 3, 1999. The termini of most eukaryotic chromosomes are com- TEP1 binds the telomerase RNA and associates with posed of terminal repeats called telomeres.
    [Show full text]
  • My Life As a Clone
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Many Voices Poetry Slam & Creative Writing Collection Libraries at University of Nebraska-Lincoln Summer 8-6-2010 My life as a clone Rajkrishna Paul University of Nebraska at Lincoln, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/manyvoicespoetry Part of the Creative Writing Commons, and the English Language and Literature Commons Paul, Rajkrishna, "My life as a clone" (2010). Many Voices Poetry Slam & Creative Writing Collection. 2. https://digitalcommons.unl.edu/manyvoicespoetry/2 This Article is brought to you for free and open access by the Libraries at University of Nebraska-Lincoln at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Many Voices Poetry Slam & Creative Writing Collection by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. MY LIFE AS A CLONE I am what, which I don’t know, of course, I am a living creature, but what exactly I am and how am I born, I didn’t got an idea. Whats my age? All of these are a hidden mystery. You might be thinking then what exactly do I want to tell you. Well I am a clone of Zehar, a scientist, he is the person who himself, cultivated a reproductive cloning on himself, to produce an exactly identical friend of his. Due to the extreme hardship for two rigorous, years, I am created, wonderfully by him. But there is some emotional sentimental part is related along my birth. I couldn’t able to accomplish true dream of Zehar, completely.
    [Show full text]
  • Gene Cloningcloningcloning
    GeneGeneGene CloningCloningCloning 20042004 SeungwookSeungwookKim Kim Chem.Chem. && Bio.Bio. Eng.Eng. Reference z T.A. Brown, Gene Cloning, Chapman and Hall z S.B. Primrose, Molecular Biotechnology, Blackwell 1 Why Gene Cloning is Important? z A century ago, Gregor Mendel : { Basic assumption (each heritable property of an organism) is controlled by a factor (gene). z In 1900, Mandel's law Æ the birth of genetics. z what these genes are and exactly how they work The Early Development of Genetics z In 1903, Sutton, W { Proposed that genes reside on chromosomes 2 z In 1910, Morgan, TH { Experimental backing on that --> development of the techniques for gene mapping (To establish the structure or structural details or location) { By 1922, a comprehensive analysis of the relative positions of over 2000 genes on the four chromosomes of the fruit fly. (Drosophilia melanogaster) z In 1944, Avery, MacLeod and McCarty z In 1952, Hershey and Chase { Experimental results were shown that DNA is the genetic material. { Conventional idea : genes were made of protein z In 1952-1966, Delbruck, Chargaff, Crick and Monod { The structure of DNA was elucidated. { The genetic code was cracked. { The process of transcription and translation were described. 3 The Advent of Gene Cloning z In the late 1960's ; The experimental techniques were not sophisticated. z In 1971 ~ 1973 ; A new experimental techniques were developed. { Recombinant DNA technology or Genetic engineering based on the process of gene cloning { This led to rapid and efficient DNA sequencing techniques that enabled the structures of individual genes to be determined. z In the 1990s ; started with massive genome sequencing projects including the human project.
    [Show full text]
  • Characterization of the Effects of Bfgf and Gsk3β Inhibitors on Embryoid
    University of Arkansas, Fayetteville ScholarWorks@UARK Theses and Dissertations 7-2015 Characterization of the Effects of bFGF and GSK3β Inhibitors on Embryoid Bodies Derived from Human Pluripotent Stem Cells Jonathan Earls University of Arkansas, Fayetteville Follow this and additional works at: http://scholarworks.uark.edu/etd Part of the Molecular Biology Commons Recommended Citation Earls, Jonathan, "Characterization of the Effects of bFGF and GSK3β Inhibitors on Embryoid Bodies Derived from Human Pluripotent Stem Cells" (2015). Theses and Dissertations. 1236. http://scholarworks.uark.edu/etd/1236 This Thesis is brought to you for free and open access by ScholarWorks@UARK. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of ScholarWorks@UARK. For more information, please contact [email protected], [email protected]. Characterization of the Effects of bFGF and GSK3β Inhibitors on Embryoid Bodies Derived from Human Pluripotent Stem Cells A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Biomedical Engineering by Jonathan Earls University of Arkansas Bachelor of Science in Physics, 1998 July 2015 University of Arkansas This thesis is approved for recommendation to the Graduate council. _____________________ Dr. Kaiming Ye Thesis Director _____________________ ______________________ Dr. Sha Jin Dr. Robert Beitle Thesis Co-director: Thesis Committee ABSTRACT Embryoid body (EB) formation is a common first step in many human pluripotent stem cell (hPSC) differentiation protocols. Previous work suggests that EBs are sensitive to growth factor withdrawal if they are derived from hPSCs maintained in feeder independent media such as mTeSR1. To promote cell survival, EBs generated from mTeSR1-adapted hPSCs are sometimes cultured in a medium that contains basic fibroblast growth factor (bFGF), a trophic factor often used in hPSC cultures to maintain self-renewal.
    [Show full text]
  • Inhibition of Human Telomerase Enhances the Effect of the Tyrosine Kinase Inhibitor, Imatinib, in BCR-ABL-Positive Leukemia Cells1
    Vol. 8, 3341–3347, November 2002 Clinical Cancer Research 3341 Advances in Brief Inhibition of Human Telomerase Enhances the Effect of the Tyrosine Kinase Inhibitor, Imatinib, in BCR-ABL-positive Leukemia Cells1 Tetsuzo Tauchi,2 Akihiro Nakajima, by only two amino acids, exhibited normal morphology. The Goro Sashida, Takashi Shimamoto, evidence of apoptosis in the telomerase-inhibited cells was Junko H. Ohyashiki, Kenji Abe, determined by flow cytometric analysis with APO2.7 mono- clonal antibody. We also observed enhanced induction of Kohtaro Yamamoto, and Kazuma Ohyashiki apoptosis by imatinib seen in DN-hTERT-expressing K562 First Department of Internal Medicine, Tokyo Medical University, cells, as compared with WT-hTERT-expressing cells. Tokyo, 160-0023 [T. T., A. N., G. S., T. S., K. O.]; Intractable Conclusions: These results demonstrate that disruption Disease Research Center, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023 [J. H. O.]; and Department of Virology, Medical of telomere maintenance limits the cellular life span of leu- Research Institute, Tokyo Medical and Dental University, Tokyo, kemia cells and show that the combined use of imatinib and 113-8519 [K. A., K. Y.], Japan telomere maintenance inhibition may be effective in the treatment of BCR-ABL-positive leukemia. Abstract Purpose: Telomerase is a ribonucleoprotein enzyme Introduction that maintains protective structures at the ends of eukary- BCR-ABL is a chimeric oncoprotein generated by recip- otic chromosomes. Earlier findings have supported an rocal translocation between chromosomes 9 and 22 and impli- association between progressive telomere shortening in cated in the pathogenesis of Ph3-positive leukemia (1). BCR- the chronic phase of chronic myelogenous leukemia and the ABL fusion proteins exhibit elevated tyrosine kinase activity up-regulation of telomerase activity occurring late in and transforming properties (2, 3).
    [Show full text]